Dr.James Pang (MD PhD)
CEO & Founder
- Over 35 years of work experience with a multidisciplinary background, including clinical practice as a surgeon, academic research in immuno-oncology, and senior/executive management in the international pharmaceutical and biotechnology industry. Extensive experience managing numerous international, multi-center clinical trials (Phases I-IV) for vaccines, anti-cancer and anti-infection drugs, and medical devices in Australia and the APAC region.
- For over 7 years, directly worked with Prof. Ian Frazer (co-inventor of the world’s first cancer vaccine, nominee for the Nobel Prize in Medicine) in Australia as his senior clinical assistant, developing the HPV vaccine against cervical cancer and sexually transmitted diseases.
- Previously held positions include Medical Clinical Director at Sirtex Medical; SVP at Shanghai Green Valley Pharmaceutical Group; VP at dMed Biopharmaceutical Co., Ltd, and CMO at Asieris Pharmaceutical; CEO of Shenzhen Constellation Biopharmaceutical Co., Ltd; and CMO (overseas) for China Grand Pharmaceutical; and General Manager of Grand Medical Pty Ltd.
- Certified Specialist in Biopharmaceutical Management from the University of Melbourne, Master of Medicine from the University of Auckland, New Zealand, and Doctor of Medicine from the Australian National University. Currently hold Guest Professor positions at Sichuan University, Wenzhou Medical University, Chongqing Medical University, and Xinjiang Shihezi University.
Ms Tiffany Wang
CEO Executive Assistant (Part-time)
- Bachelor of Nursing Science student at the University of the Sunshine Coast
- Experience in personal assistance, administrative support, disability services, and aged care
- Strong organisational, communication, and coordination skills, with careful attention to detail and professionalism
- Provides reliable support in documentation, client communication, follow-up tasks, and day-to-day operations
- Proven leadership background through school prefect, student mentoring, and public speaking responsibilities
- Brings a caring, proactive, and people-focused approach to every role
Jason Zhang
Key Business Partners & Chief Finance Officer
- Chartered Accountant (CA), Certified Public Accountant (CPA), and Chartered Tax Adviser
- Over 15 years of working experience of accounting, taxation and business advisory services to a broad spectrum of clients ranging from high-net-worth individuals to large enterprises and subsidiaries of foreign multinationals
- Advisor to a number of ASX companies and NFP boards.
- Expertise in international tax with a strong track record of providing practical and value-driven strategic tax solutions to clients.
- Regularly assists clients with M&A, due diligence, and cross-border joint venture tasks.
- A member of Chartered Accountants Australia and New Zealand and Chartered Tax Advisor accredited by The Tax Institute
Neil Finlayson (BSc -Hons, BCom), (Director: Neil Finlayson Consulting)
Chief Operating Officer (COO)
- Over 30 years of work experience in management, clinical development and commercialisation within the biotechnology sector. Held senior roles in business development and been CEO for a number of clinical stage biotech companies. Extensive experience in clinical trials (Phases I and II), banking and finance, Joint Ventures, partnering and out-licensing, and in company formations
- Previously, CEO of DNA vaccine developer Admedus Vaccines Pty Ltd, founded by Prof. Ian Frazer (co-inventor of the world’s first cancer vaccine)
- Previously held positions include Director and CEO of Jingang Medicine (Australia) Pty Ltd; CEO of Vaccine Solutions Pty Ltd (co-owned by CSL Limited and QIMR Berghofer); Executive Officer of the Cooperative Research Centre for Vaccine Technology (a $42M joint venture); Business Development Director of Bio Innovation SA; Founding Director of AbRegen Pty Ltd; and Director of Commercialisation at Griffith University
- Previously member of the Australian Association of Angel Investors Limited; the Australian Institute of Company Directors; and the University of South Australia, School of Pharmacy and Medical Sciences Pharmaceutical Science Advisory Committee
Nicoletta Muner (BPharm -Hons, MPharmSci, GAICD, MMPP), (Founder and Managing Director: Canary Regulatory Affairs)
Senior Vice President – Global Regulatory Affairs
- More than 25 years experience in the pharmaceutical industry, spanning product, pre-clinical and clinical development, and international regulatory affairs
- Expert in global regulatory strategy development and in obtaining scientific advice from the EMA, EU National Competent Authorities, FDA (Pre-IND, Type C, EOP2, Pre-NDA/BLA), MHRA and TGA
- Extensive experience in regulatory submissions, including Orphan Drug Designation (ODD), Rare Pediatric Disease Designation (RPDD), accelerated pathways, IND application, Pediatric Study/Investigational Plans (PSP/PIP), New Drug Application (NDA) submissions and EU Marketing Authorisation Application (MAA) filings via Centralised and Decentralised Procedures
- Successfully registered a first-in-class orphan medicinal product in the European Union and the United States
- Experienced in the design and project management of nonclinical studies
- Experienced in the preparation of Investigator’s Brochures and Clinical Study Protocols
- Bachelor’s degree in Pharmaceutical Chemistry and Technologies from the University of Trieste (Italy) including a research project conducted at the University of Regensburg (Germany)
- Awarded First-Class Honours and Master’s degree in Pharmaceutical Sciences from Monash University (Australia)
- Graduate of the Australian Institute of Company Directors (AICD)
Andrew Jaworski (LLB (Hons), BOptom, GradDipLaw (Comm), GradCert TMLP, AFCHSM, CHM, GAICD, CIPT, CIPM, FGIA)
Senior Vice President – Legal and Business Affairs
- Dual-qualified lawyer admitted in Australia and England & Wales, with more than 20 years’ experience across corporate and commercial law and deep experience in the health, research and technology sectors.
- Managing Principal of First Port Legal, with senior executive experience across Big 4 advisory, international top-tier law firms, global multinationals and the public sector in the UK, APAC and ASEAN regions.
- Routinely advises boards, founders and executive teams on corporate and commercial matters, including M&A, joint ventures, strategic partnerships, risk management, compliance, privacy, AI, technology, IP and cross-border transactions.
- Graduate of the Australian Institute of Company Directors and Fellow of the Governance Institute of Australia, with several non-executive director, company secretary and advisory board member roles, advising on governance, compliance and regulatory frameworks across the private, public and not-for-profit sectors.
- Award winning lawyer, with recent recognition as Sole Legal Counsel of the Year at the Lawyers Weekly Corporate Counsel Awards 2026, and broader industry recognition with awards across health/biotech, not-for-profit and professional excellence.
Dr.Qiao Wang (MD)
VP - Medical Clinical Affairs
- Master of Biotechnology, University of Wollongong, Australia; Master of Medical Science, University of Queensland, Australia
- Over 20 years of R&D experience at multinational pharmaceutical companies including Pfizer, Novartis, and Johnson & Johnson. Held positions as Physician, Franchise Head, and Compound Team Lead
- Rich experience in leading the development of multiple compounds/indications across diverse fields, including Oncology, Ophthalmology, central nervous system, pulmonary arterial hypertension, rare diseases, gene therapy, and more
Dr.Pavel Reddy
Key Business Partners & Senior R&D Tax Advisor
- Over 17 years of experience as an R&D Tax Advisor. Registered with the Australian Tax Practitioners Board. Proven track record working with Big 4 consulting firms and leading Australian R&D Tax Consultancies.Extensive experience working with companies across various industries, from startups to multinational corporations.
- Global network: Collaborates with government departments, incubators, accelerators, and tech companies in Biotech, Life Sciences, MedTech, and Pharma across China, EU, Singapore, South Korea, UK, and the USA.
- Diverse expertise: Identifies eligible R&D activities across various sectors due to a varied background and experience. Consulting experience spans life sciences, IT, food & beverage, engineering, and manufacturing.
- Proven track record: Successfully submitted and defended numerous clients’ R&D tax claims, prepared and lodged Advance and Overseas Findings.
- Academic background: PhD in Biological Sciences. Previously lectured at three tertiary institutions for 18 years. Conducts both personal and collaborative research, with publications in peer-reviewed scientific journals.
Professor Jack Wong
Non-Executive Director & Regulatory Affairs Expert
- Over 25 years of experience in regulatory and quality network in APAC including Australia and New Zealand with good knowledge in the field of Nutritional, Pharmaceuticals, Medical Devices, Consumer Healthcare and Biological products
- Founder of the biggest regulatory association with over 7000 members in the APAC region
- Author of many Handbooks of Regulatory Affairs in Asia and developed many training courses in regulatory affairs
- Adjunct Professor/Lecturer in Chinese University of Hong Kong, National University of Singapore and Tohoku University Japan
- CEO of RNAscence (a Biotech startup spin off from Nanyang Technological University and National Skin Center Singapore)
Dr. Audrey Jia (MD, PhD, MS)
Non-Executive Director & Former FDA Senior CMC Reviewer
- More than 20 years of combined experience in biologic product development and the FDA CMC review
- Very experienced in IND and BLA review
- Very experienced in GMP mock inspections of biologics and small molecules
- Strong experience in US/China regulatory strategy
- Experienced in novel and biosimilar for Mab, Bispecific, ADC, cytokines, peptide, insulin, mRNA vaccines etc
- M.D., Peking University; Ph.D. in Biochemistry, Emory University; M.S. in Bioscience Regulatory Affairs, Johns Hopkins University
Stella Chen
Non-Executive Director & Medical Device Registration Expert
- Over 20 years of experience in pharmaceutical and medical device regulatory registration and quality management, with expertise in registration, clinical trials, and international certification
- Led the establishment of quality systems in more than 10 subsidiaries of the AILEX Group, passing multiple regulatory inspections by drug administration bureaus and TÜV Süd
- Secured over 200 medical device registration certificates, with Class III devices accounting for more than 10%
- Served in quality management roles in several well-known pharmaceutical companies and has been with the AILEX Group for over a decade. Currently serves as the General Manager of Shinying Medical Devices, focusing on global registration and consulting services
- Holds an MBA in Big Health Industry from East China University of Science and Technology and a Bachelor’s degree in Pharmacy from Zhejiang Chinese Medical University
- A licensed pharmacist and the head of the Big Health Industry Management Club at East China University of Science and Technology
Ding Yi Xu
Executive Consultant - R&D Strategy (New Zealand)
- 1982 BEng, Shanghai Jiaotong University,1987 MEng, Auckland University
- Shanghai Second Medical University, Lecture
- Molecular Medicine Department, Auckland Medical School, Research Scientist
- Genesis Research & Development Corp (NZ) Ltd, Head of IT & Bioinformatics
- Psychiatric Genomics (USA) Inc., Director of IT & Bioinformatics
- New Zealand Science Technology and Education Promotion Centre, Director
Shanghai Jiaotong University (NZ) Alumni, VP - New Zealand-China Association for the Promotion of Economy& Science, Exec VP
- New Zealand Institute of Environment Science & Research (ESR), Principal Advisor
- Otago University Business School, Principal Advisor
- Otago Polytechnic (Auckland International Campus), Senior Advisor
Dr. Marissa Lim (BMedSc, MBBS, MBA )
Senior Medical Director
- Registered medical practitioner with over two-decades of experience within the Pharmaceutical Industry including Servier, BMS, Vifor Pharma and Ipsen.
- Expertise encompasses drug development, clinical research spanning Phase 1 to Phase 3 trials and investigator led projects, medical monitoring and drug safety management, ethics, compliance, and product launch preparedness.
- Held positions as country and regional Medical Director as well as Global Medical Director and Chief Medical Officer roles. Provide medical leadership in crucial medical strategies throughout the entire life cycle of a product, from clinical development to launch.
- Extensive experience in designing clinical trials from Phase 1 to Phase 3, and across multiple therapeutic areas including oncology, general haematology, dermatology, wounds and patient blood management.
- Highly experienced medical monitor and medical advisor.